Nelarabine (brand name Arranon/Atriance), is a chemotherapy agent introduced for treating patients with T-cell acute lymphoblastic leukemia (T-ALL). It is also used for treating T-cell lymphoblastic lymphoma (T-LBL). The standard dose of nelarabine injection should be administered intravenously (into a vein) by a healthcare professional in a hospital or clinic.
The acute lymphocytic leukemia therapeutics market was valued at $1.96 billion in 2010 and is expected to reach $3.88 billion by 2020, at a CAGR of 5.21% between 2015 and 2020. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen. The chemotherapy drug regimens were dominated by Hyper-CVAD regimen sales, totaling $1.8 billion and linker regimen sales totaling $1.13 billion sales in acute lymphocytic leukemia market.
Chemotherapy administration services: CPT codes 96400, 96408 to 96425, 96520 and 96530 Therapeutic or diagnostic infusions (excluding chemotherapy): CPT codes 90780 to 90781 Drug injection codes (90782 to 90788) are paid under the Medicare physician fee schedule. For chemotherapy administration services furnished prior to January 1, 2004, the carrier allowed CPT code 96408 (Chemotherapy administration, intravenous; push technique) to be reported only once per day, even if the physician administered multiple drugs.
The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials).
Conducted by scientists employed by the Federal government ... Over 80 collaborative agreements (CRADAs, CTAs, and CSAs) with pharmaceutical companies ...
Mailman Center for Child Development Department of Pediatrics ... Omission Errors 65 (Within Normal Range) 65 (Clinically Significant) CPT Scale. Background ...
Oncology Products. Division of Medical. Imaging and. Hematology Products. 4 ... Includes drugs/biologics reviewed in Office of Oncology Drug Products ...